Effects of antileukotrienes in the treatment of asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 2 II, 2000, Pages

  Barnes, N C ^a  

^a LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PRANLUKAST; SINGULAR; UNCLASSIFIED DRUG; ZAFIRLUKAST; ZILEUTON;

ASTHMA; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; PRIORITY JOURNAL; REVIEW;

EID: 0034014625     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.supplement_1.ltta-15     Document Type: Review

References (37)

1. Nasser, S. M. S., and T. H. Lee. 1998. Cysteinyl leukotriene receptor antagonists and 5-lipoxygenase inhibition in asthma. In J. M. Drazen, S. E. Dahlen, and T. H. Lee, editors. The Lung in Health and Disease, Vol. 120: 5-Lipoxygenase Products in Asthma. Marcel Dekker, New York.
2. Carter G. W., P. R. Young, D. H. Albert, J. Bouska, R. Dyer, R. L. Bell, J. B. Summers, and D. W. Brooks. 1991. Five-lipoxygenase inhibitory activity of zileuton. J. Pharmacol. Exp. Ther. 256:929-937.
3. 4-receptor antagonist. Can. J. Physiol. Pharmacol. 73:191-201.
4. Dubb, J. W., and A. S. Rebuck. 1998. Pranlukast - the first orally active cysteinyl leukotriene receptor antagonist marketed for the treatment of asthma. In J. M. Drazen, S. E. Dahlen, and T. H. Lee, editors. The Lung in Health and Disease, Vol. 120: 5-lipoxygenase Products in Asthma. Marcel Dekker, New York. 347-363.
5. Krell, R. D., D. Aharony, C. K. Buckner, R. A. Keith, D. W. Snyder, P. R. Bernstein, V. G. Matassa, Y. K. Lee, and F. J. Brown. 1990. The preclinical pharmacology of ICI-204,219, a peptide leukotriene antagonist. Am. Rev. Respir. Dis. 141:978-987.
6. 4 in bronchoalveolar lavage in bronchial asthma and other respiratory disease. J. Allergy Clin. Immunol. 84:19-26.
7. Hui, K. P., and N. C. Barnes. 1991. Lung function improvement in asthma with a cysteinyl leukotriene receptor antagonist. Lancet 337:1062-1063.
8. 4 antagonist, MK-679. Am. Rev. Respir. Dis. 147:1442-1446.
9. Reiss, T. F., C. A. Sorkness, W. Strickler, A. Botto, W. W. Busse, S. Kundu, et al. 1997. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, or bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 52:45-48.
10. Israel, E., P. Rubin, J. P. Kemp, J. Grossman, et al. 1993. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann. Intern. Med. 119:1059-1066.
11. 4 in normal subjects. Am. Rev: Respir. Dis. 133:1127-1132.
12. Reiss, T. F., P. Chervinsky, R. J. Dockhorn, et al. 1998. Montelukast, a once-daily receptor antagonist, in the treatment of chronic asthma. A multicentre, randomised, double-blind trial. Arch. Intern. Med. 158:1213-1220.
13. 4 receptor antagonist in subjects with bronchial asthma. Am. J. Respir. Crit. Care Med. 150:618-623.
14. Barnes, N. C., B. Black, N. Syrett, et al. 1996. Reduction of exacerbations of asthma in multinational trials with zafirlukast (Accolate). Allergy 51(Suppl. 30):84.
15. The British Thoracic Society, et al. 1997. The British guidelines on asthma management 1995 review and position statement. Thorax 52: S1-S21.
16. National Institutes of Health, National Heart, Lung, and Blood Institute. 1995. Global initiative for asthma. Asthma management and prevention: a practical guide for public health officials and health care professionals. NIH Publication No. 96-3695A.
17. Laviolette, M., K. Malmstrom, S. Lu, P. Chervinsky, J.-C. Pujet, I. Peszek, J. Zhang, and T F. Reiss. 1999. Montelukast added to inhaled beclomethasone in treatment of asthma. Am. J. Respir. Crit. Care Med. (In press)
18. Nayak, A. S., P. Anderson, B. L. Kharous, K. Williams, S. Simonson. 1998. Equivalence of adding zafirlukast versus double-dose inhaled corticostcroids in asthmatic patients symptomatic on low dose inhaled corticosteroids (abstract). J. Allergy Clin. Immunol. 101(Pt. 2):S333.
19. Virchow, J. C., S. M. Hassall and A. Harris. 1997. Improved asthma control over 6 weeks with zafirlukast in patients on high dose inhaled corticosteroids (abstract). Eur. Respir. J. 10(Suppl. 25):437S.
20. Virchow, J. C., S. M. Hassall, L. Summerton, J. Klim, and A. Harris. 1997. Reduction of asthma exacerbations with zafirlukast in patients on inhaled corticosteroids (abstract). Eur. Respir. J. 10(Suppl. 25):420s.
21. Bateman, E. D., S. T. Holgate, B. M. Binks, and I. P. Tams. 1995. A multicenter study to assess the steroid-sparing potential of Accolate (zafirlukast 20 mg b.d.) (abstract). Allergy 50(Suppl. 26):320.
22. Laitinen, L. A., O. Zetterstroem, S. T. Holgate, S. M. Binks, and J. G. Whitney. 1995. Effects of Accolate (zafirlukast 20 mg. b.d.) in permitting reduced therapy with inhaled steroids: a multicenler trial in patients with doses of inhaled steroid optimised between 800 and 2,000 μg per day (abstract). Allergy 50(Suppl. 26):320.
23. Lofdähl, C.-G., T. F. Rciss, J. A. Leff, E. Israel, M. J. Noonan, A. F. Finn, B. C. Seidersberg, T. Capizzi, S. Kunda, and P. Godard. 1999. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. B.M.J. 319: 87-90.
24. 4 excretion. Am. Rev. Respir. Dis. 147:1472-1476.
25. 1 receptor antagonist: Correlations with patient baseline characteristics. Eur. Respir. J. (In press)
26. Knorr, B., J. Matz, J. A. Bernstein, et al. 1998. Montelukast for chronic asthma in 6 to 14 year old children: a randomised, double-blind trial. J.A.M.A. 279:1181-1186.
27. Holgate, S. T., K. D. Anderson, and E. M. Rodgers. 1995. Comparison of "Accolate" (zafirlukast) with sodium cromoglycate in mild to moderate asthmatic patients (abstract). Allergy 50(Suppl. 26):319-320.
28. Nathan, R. A., M. Glass, and L. Snader. 1995. Effects of 13 weeks of treatment with ICI-204,219 (Accolate) or cromolyn sodium ("Intal") in patients with mild to moderate asthma (abstract). J. Allergy Clin. Immunol. 95(Pt. 2):388.
29. Malmstrom, K., G. Rodriguez-Gomez, J. Guerra, C. Villaran, A. Pineiro, L. X Wei, B. C. Seiderberg, and T. F. Reiss. 1999. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. Ann. Intern. Med. 130:487-195.
30. Laitinen, L. A., I. P. Naya, S. Binks, and A. Harris. 1997. Comparative efficacy of zafirlukast and low dose steroids in asthmatics on pm β2 agonists (abstract). Eur. Respir. J. 10(Suppl. 25):4195-4205.
31. Kalberg, C. J., M. J. Johnson, S. Srebro, and K. A. Rickard. 1998. A comparison of salmeterol and zafirlukast in the treatment of persistent asthma (abstract). Thorax 53(Suppl 4): A16
32. 4 induced bronchoconstriction in normal man. J. Allergy Clin. Immunol. 79:816-821.
33. 4 receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am. Rev. Respir. Dis. 140:1336-1339.
34. Merck Sharp Dohme. 1999. Singulair data sheet.
35. Barnes, N. C., B. J. Lavins, C. J. Miller, J. Cohn, and V. Perrin. 1997. Safety and tolerability of zafirlukast ("Accolate"), a new treatment for asthma (abstract). Am. J. Respir. Crit. Care Med. 155(Suppl.):A663.
36. Abhott Laboratories. 1998. Zyflo package insert. Abbott Laboratories, North Chicago. IL.
37. Vargo, D. L., C. Yeh, C. D. Kare, and B. K. Birmingham. 1997. Effect of zafirlukast on prothrombin time and area under the curve of warfarin (abstract). Allergy 52(Suppl. 37):188.